Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Amrita V. Kamath"'
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 32, Iss 3, Pp 101326- (2024)
An understanding of recombinant adeno-associated virus (AAV) biodistribution profiles is an important element of a preclinical development program. Here, we have developed a radiolabeling strategy utilizing the co-delivery of 125I (non-residualizing)
Externí odkaz:
https://doaj.org/article/14d8f04b89cf414ea37ab440985e97cc
Autor:
Rajbharan Yadav, Suzanne Schubbert, Patrick G. Holder, Eugene Y. Chiang, Nargess Kiabi, Liz Bogaert, Irene Leung, Rumana Rashid, Kendra N. Avery, Christine Bonzon, John R. Desjarlais, Shomyseh Sanjabi, Amy Sharma, Michelle Lepherd, Amy Shelton, Pam Chan, Yanqiu Liu, Louis Joslyn, Iraj Hosseini, Eric G. Stefanich, Amrita V. Kamath, Matthew J. Bernett, Vittal Shivva
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionInterleukin 15 (IL-15) is a potential anticancer agent and numerous engineered IL-15 agonists are currently under clinical investigation. Selective targeting of IL-15 to specific lymphocytes may enhance therapeutic effects while helping t
Externí odkaz:
https://doaj.org/article/31030b79b4034614806d2f9e04a075ba
Autor:
Iraj Hosseini, Brett Fleisher, Jennifer Getz, Jérémie Decalf, Mandy Kwong, Meric Ovacik, Travis W. Bainbridge, Christine Moussion, Gautham K. Rao, Kapil Gadkar, Amrita V. Kamath, Saroja Ramanujan
Publikováno v:
Pharmaceutics, Vol 16, Iss 5, p 660 (2024)
FLT3L-Fc is a half-life extended, effectorless Fc-fusion of the native human FLT3-ligand. In cynomolgus monkeys, treatment with FLT3L-Fc leads to a complex pharmacokinetic/pharmacodynamic (PK/PD) relationship, with observed nonlinear PK and expansion
Externí odkaz:
https://doaj.org/article/2aeee9c733c94287888bd277150996d7
Autor:
Karelle Ménochet, Hongbin Yu, Bonnie Wang, Jay Tibbitts, Cheng-Pang Hsu, Amrita V. Kamath, Wolfgang F. Richter, Andreas Baumann
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
Monoclonal antibodies (mAbs) deliver great benefits to patients with chronic and/or severe diseases thanks to their strong specificity to the therapeutic target. As a result of this specificity, non-human primates (NHP) are often the only preclinical
Externí odkaz:
https://doaj.org/article/0dd48640109d457fb44fab13cc929494
Autor:
Hanine Rafidi, Sharmila Rajan, Konnie Urban, Whitney Shatz-Binder, Keliana Hui, Gregory Z. Ferl, Amrita V. Kamath, C. Andrew Boswell
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
Advances in antibody engineering have enabled the construction of novel molecular formats in diverse shapes and sizes, providing new opportunities for biologic therapies and expanding the need to understand how various structural aspects affect their
Externí odkaz:
https://doaj.org/article/6c3322f467974ab2941978a377de89ce
Autor:
Vittal Shivva, C. Andrew Boswell, Hanine Rafidi, Robert F. Kelley, Amrita V. Kamath, Susan R. Crowell
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Protein therapeutics have witnessed tremendous use and application in recent years in treatment of various diseases. Predicting efficacy and safety during drug discovery and translational development is a key factor for successful clinical developmen
Externí odkaz:
https://doaj.org/article/50f86463d5604cc1aa17812805e6ac05
Autor:
Chunze Li, Cindy Zhang, Rong Deng, Douglas Leipold, Dongwei Li, Brandon Latifi, Yuying Gao, Crystal Zhang, Zao Li, Dale Miles, Shang‐Chiung Chen, Divya Samineni, Bei Wang, Priya Agarwal, Dan Lu, Saileta Prabhu, Sandhya Girish, Amrita V. Kamath
Publikováno v:
Clinical and Translational Science, Vol 12, Iss 5, Pp 534-544 (2019)
Prediction of human pharmacokinetics (PK) based on preclinical information for antibody–drug conjugates (ADCs) provide important insight into first‐in‐human (FIH) study design. This retrospective analysis was conducted to identify an appropriat
Externí odkaz:
https://doaj.org/article/093a7f985ba448568183151dc8157a3a
Autor:
Rajbharan Yadav, Siddharth Sukumaran, Tanja S. Zabka, Jinze Li, Amy Oldendorp, Gary Morrow, Arthur Reyes, Melissa Cheu, Jessica Li, Jeffrey J. Wallin, Siao Tsai, Laura Sun, Peiyin Wang, Diego Ellerman, Christoph Spiess, Andy Polson, Eric G. Stefanich, Amrita V. Kamath, Meric A. Ovacik
Publikováno v:
Pharmaceutics, Vol 14, Iss 5, p 970 (2022)
The T cell-dependent bispecific (TDB) antibody, anti-CD79b/CD3, targets CD79b and CD3 cell-surface receptors expressed on B cells and T cells, respectively. Since the anti-CD79b arm of this TDB binds only to human CD79b, a surrogate TDB that binds to
Externí odkaz:
https://doaj.org/article/c576a9c94d774c0bbfd8b9f7d710cb3d
Autor:
Daniela Bumbaca Yadav, Arthur E. Reyes II, Priyanka Gupta, Jean‐Michel Vernes, Y. Gloria Meng, Michelle G. Schweiger, Shannon L. Stainton, Germaine Fuh, Paul J. Fielder, Amrita V. Kamath, Ben‐Quan Shen
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 2, Pp n/a-n/a (2020)
Abstract A phage‐derived human monoclonal antibody against VEGF‐C was developed as a potential anti‐tumor therapeutic and exhibited fast clearance in preclinical species, with notably faster clearance in serum than in plasma. The purpose of thi
Externí odkaz:
https://doaj.org/article/a2642f34ca374b879cf1e05fa87c259f
Autor:
C. Andrew Boswell, Gregory Z. Ferl, Amrita V. Kamath, Shang-Fan Yu, Mary Ann T. Go, Christoph Spiess, T. Noelle Lombana, Sheila Ulufatu, Jason Ho, Alecia T. Dent, Anna King, Lauren N. Sermeño, Danielle Mandikian, Madeleine K. Ramos
Supplementary Data and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d20dbeeb5c28537bd9c83b666eae461
https://doi.org/10.1158/1535-7163.22520782.v1
https://doi.org/10.1158/1535-7163.22520782.v1